Article info

Download PDFPDF

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

Authors

  1. Correspondence to Professor Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; mail{at}dvanderheijde.nl
View Full Text

Citation

van der Heijde D, Gensler LS, Deodhar A, et al
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

Publication history

  • Received January 14, 2020
  • Revised February 25, 2020
  • Accepted February 25, 2020
  • First published April 6, 2020.
Online issue publication 
April 15, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.